We offer a wide range of tools and services to support translational research, clinical development, commercial access, and companion diagnostics. We utilize multi-omics, transcriptomics, and genomic testing services powered by our extensive databases and cutting-edge analytics to empower pharmaceutical partners at every stage of their cancer research and drug development, ensuring confidence in their progress. We provide essential data on patient biomarkers, genomics, and disease characteristics, guiding researchers in understanding disease mechanisms, developing treatments, and bridging the gap between lab discoveries and clinical applications to enhance patient outcomes.
We support clinical development by helping to identify suitable patients, monitor treatment effectiveness, and ensure safety. These capabilities help inform trial design, optimize patient selection, and advance new cancer treatments.
We facilitate commercial access by providing evidence of clinical utility, aiding regulatory approvals, and guiding reimbursement strategies. This information enables successful market entry for new drugs and associated therapies, enhancing commercialization efforts.
Through our end-to-end service model, we identify target patient populations and support the full companion diagnostics process, including assay development, manufacturing, and commercialization. Our comprehensive suite of multi-omics testing services is built on a foundation of deep expertise in genomics, proteomics, transcriptomics, and more.
This empowers us to precisely match the most suitable technologies to the specific requirements of our biopharmaceutical partners in their pursuit of innovative oncology drug development solutions. We offer spatial biology and image analysis, multiplex assays, and custom IHC panels to provide actionable and efficient insights into the tumor microenvironment TME.
